科研之友
微信
新浪微博
Facebook
分享链接
摘要
Objective: We aimed to investigate the safety and efficiency of vinorelbine/epirubicin/fluorouracil(NEF) regimen as adjuvant chemotherapy for breast cancer. Methods: From 2005 to 2008, 227 female breast cancer patients were treated with the NEF regimen: vinorelbine 25 mg/m2 iv on days 1 and 8; epirubicin 60 mg/m2 iv gtt on day 1; 5-Fu 500 mg/m2 iv gtt on day 1. Chemotherapy was repeated every 21–28 days for a total of 6 cycles. Results: The major side effects were neutropenia and gastrointestinal syndrome, with a 5-year survival rate of 85.4%. Conclusion: NEF regimen is safe and guarantees a high survival rate which could be recommended as a adjuvant chemotherapy regimen for breast cancer.
